Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Teva
US Department of Justice
QuintilesIMS
Cerilliant
McKinsey
Baxter
Cantor Fitzgerald
Accenture

Generated: May 20, 2018

DrugPatentWatch Database Preview

HALFAN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Halfan patents expire, and what generic alternatives are available?

Halfan is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in HALFAN is halofantrine hydrochloride. Additional details are available on the halofantrine hydrochloride profile page.
Summary for HALFAN
Drug patent expirations by year for HALFAN
Synonyms for HALFAN
(1)-Halofantrine
1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl
1-[-1,3-dichloro-6-trifluoromethyl-9-phenanthryl]-3-di(n-butyl)aminopropanol
1-[1,3-bis(chloranyl)-6-(trifluoromethyl)phenanthren-9-yl]-3-(dibutylamino)propan-1-ol;hydrochloride
1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6- (trifluoromethyl)-9-phenathrenemethanol
1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol
1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol
1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemetnaol
3-(Dibutylamino)-1-(1,3-dichlor-6-(trifluormethyl)-9-phenanthryl)propanol
3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthrenyl]-1-propanol
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthrenyl]-1-propanol;hydrochloride
3-(Dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]-1-propanol
3-(Dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]-1-propanol #
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]propan-1-ol
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]propan-1-ol;hydrochloride
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol;hydrochloride
66051-63-6
69756-53-2
9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-
9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1)
9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
9-Phenanthrenemethanol, 1,3-dihydro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-
AB0014069
AB00514703
AC-481
AC1L1XMN
AC1Q4K45
AK115822
AKOS015907678
AN-15830
API0002883
AS-14162
AS-839/43469859
AX8042604
BC219545
BDBM79214
BPBio1_001366
BSPBio_001241
C-22940
C07634
CC-29129
CHEBI:94392
CHEMBL1107
cid_37392
D07MVK
D08033
DB01218
dl-WR 171669
DR003065
DTXSID0023119
FOHHNHSLJDZUGQ-UHFFFAOYSA-N
FT-0601579
Halfan (TN)
Halofantrina
Halofantrina [INN-Spanish]
Halofantrine
Halofantrine (INN)
Halofantrine [INN:BAN]
Halofantrine [USAN]
Halofantrine HCl
Halofantrino
Halofantrinum
Halofantrinum [INN-Latin]
I14-2822
K173
KB-233537
LP106649
LS-187198
MLS002154111
MLS006010152
MolPort-005-940-418
NCGC00179250-01
NCGC00179250-04
NCI60_002593
Prestwick0_001031
Prestwick1_001031
Prestwick2_001031
Prestwick3_001031
R7ADS21FSN
SCHEMBL43795
SK&F-102866
SMR001233418
SMR004701269
SPBio_003092
UNII-R7ADS21FSN
WR 171,699
WR-171699

US Patents and Regulatory Information for HALFAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline HALFAN halofantrine hydrochloride TABLET;ORAL 020250-001 Jul 24, 1992 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Accenture
Cantor Fitzgerald
Federal Trade Commission
Covington
Mallinckrodt
Queensland Health
US Department of Justice
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.